Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

By afschroeder • October 8, 2025

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy. Front Oncol. 2025 Sep 22;15:1649493. doi: 10.3389/fonc.2025.1649493. PMID: 41059291; PMCID: PMC12497632.

Tags: antagonists, clinical efficacy, combination drug therapy, drug administration schedules, exportin 1, Hematology/Oncology, inhibitors, Multiple myeloma, Publications, selinexor

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG,[...]